ArticleJournal of thoracic disease2026
Focus on pleural empyema: etiology, epidemiology, infectiology, treatment, and impact of the COVID-19 pandemic-a single-center analysis.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pleural empyema is a potentially life-threatening condition requiring timely interdisciplinary management. Based on the underlying pathophysiology, empyema is classified into three stages: exudative (stage I), fibrinopurulent (stage II), and chronic-organizing (stage III). Despite advances in surgical techniques and perioperative care, pleural empyema remains associated with considerable morbidity. Data on changes in incidence and management during the coronavirus disease 2019 (COVID-19) pandemic remain limited. This study aims to analyze etiology, epidemiology, infectiology, and surgical treatment of pleural empyema, with particular focus on the impact of the COVID-19 pandemic. Methods: This retrospective single-center study included all patients surgically treated for pleural empyema between January 2018 and December 2022 at a high-volume thoracic surgery center. Patient characteristics, etiology, empyema stage, microbiological findings, operative approach and length of hospital stay were analyzed. Case numbers before and during the COVID-19 pandemic were compared. Results: A total of 282 patients were included. Parapneumonic empyema was the most frequent etiology (62%), followed by postoperative empyema (17%). Intraoperative microbiological cultures were positive in 36% of cases, with streptococci predominating in parapneumonic empyema and staphylococci in postoperative cases. During the COVID-19 pandemic, particularly in 2020 and 2021, a significant reduction in surgically treated pleural empyema was observed. Advanced-stage (stage III) empyema was associated with significantly longer operative times, prolonged chest tube duration, and extended hospital stay. In the majority of patients, a minimally invasive approach was employed. Conclusions: Parapneumonic infection was the predominant cause of pleural empyema, while microbiological pathogen detection remained limited. During the COVID-19 pandemic, a significant decrease in surgically treated empyema cases was observed. Advanced-stage disease was associated with increased operative complexity and prolonged postoperative recovery. In a specialized thoracic surgery setting, video-assisted thoracoscopic surgery constitutes the standard surgical approach, even in chronic pleural empyema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.